The Effect of Roaccutane on Development of Ovarian Follicles and Uterine Changes in Adult NMRI Mice Strain
Archives of Advances in Biosciences,
Vol. 12 No. 2 (2021),
9 May 2021
,
Page 1-9
https://doi.org/10.22037/aab.v12i2.34263
Abstract
Introduction: Roaccutane, Acuten, and Isotretinoin are derivatives of the vitamin A naturally found in human body. Since vitamin A is a fat-soluble vitamin, it is prescribed through controlling the amount of skin oil by forcing low-secreted sebaceous glands to treat severe skin acne with the risk of permanent scarring. Thus, we aimed to investigate the effects of Roaccutane on evolution of ovarian follicles and uterine, and possible attendant liver changes in adult NMRI mice.
Materials and Methods: Roaccutane was orally administered by gavage at the doses of 0.5, 10, and 20 mg/kg for 21 days. Then, the mice were dissected, and the uterine, ovarian, and liver tissues were separated. The levels of Estradiol (E2), Follicle-stimulating hormone (FSH), Alanine transaminase (ALT), Aspartate transaminase (AST), and Alkaline phosphatase (ALP) were examined by ELISA test and chlorometric biochemical method.
Results: Increase in the Roaccutane dose led to the damage to endometrium layers, and there were no significant changes in myometrium and perimetrium. Observations of the tissue of ovaries indicated the maturity of them. Significant reduction in the number of hepatocytes and rise of glands and blood vessels were the results of the liver damage. High level of liver enzymes (ALT, AST, and ALP) was the important reason for the liver damage. Hormonal findings through the increase of E2 and FSH also showed tissue damage.
Conclusion: The results revealed the harmful effect of Roaccutane on evolution of ovarian follicles and uterine and liver changes of adult laboratory NMRI mice (either tissue or hormone).
- Roaccutane; Isotretinoin; NMRI mice; ovarian follicle; E2; FSH; ALT; AST; ALP
How to Cite
References
2. Marasca, C., et al., Comment on 'The effects of isotretinoin therapy on serum homocysteine, folate and vitamin B12 levels in patients with acne': may retinoids be useful to treat hyperhomocysteinemia found in patients affected by hidradenitis suppurativa? J Eur Acad Dermatol Venereol, 2020. 34(3): p. e120-e121.
3. Wessels, F., A.N. Anderson, and K. Kropman, The cost-effectiveness of isotretinoin in the treatment of acne. Part 2. A chronic medication plan profiling study. S Afr Med J, 1999. 89(7 Pt 2): p. 785-90.
4. McLaughlin, J., et al., Propionibacterium acnes and Acne Vulgaris: New Insights from the Integration of Population Genetic, Multi-Omic, Biochemical and Host-Microbe Studies. Microorganisms, 2019. 7(5).
5. Wu, Y., et al., Inhibitory effect of the antimicrobial peptide BLP-7 against Propionibacterium acnes and its anti-inflammatory effect on acne vulgaris. Toxicon, 2020. 184: p. 109-115.
6. Ladan, D., Check the resistance of propioni bacterium Acne in comparison with antibiotics to patients with vulgaris acne. Quarterly of Skin disease, 2002.
7. Naimeh Farhidnia and Azadeh Memarian, Congenital anomalies following use of isotretinoin: Emphasis on its legal aspects. Med Leg J, 2017. 85(1): p. 33-34.
8. Tchernev, G., Folliculitis et perifolliculitis capitis abscedens et suffodiens controlled with a combination therapy: systemic antibiosis (metronidazole plus clindamycin), dermatosurgical approach, and high-dose isotretinoin. Indian J Dermatol, 2011. 56(3): p. 318-20.
9. Bidoli, P., et al., Isotretinoin plus clindamycin seem highly effective against severe erlotinib-induced skin rash in advanced non-small cell lung cancer. J Thorac Oncol, 2010. 5(10): p. 1662-3.
10. M.Freund, R.Csikos, and S.Keszthelyi, Parraffin products properties, technologies, applications. 1982.
11. Schnurmann, R., P.M. Martin, and W.F. Maddams, An ultraviolet spectrophotometric quality and stability criterion for medicinal liquid paraffin. J Pharm Pharmacol, 1951. 3(5): p. 298-301.
12. Ebrahimi Daryani, N., et al., Liver Enzyme Alteration. JOURNAL OF MEDICAL COUNCIL OF IRAN, 2012. 30(3): p. 272-287.
13. Farhidnia, N. and A. Memarian, Congenital anomalies following use of isotretinoin: Emphasis on its legal aspects. Medico-Legal Journal, 2017. 85(1): p. 33-34.
14. Henry, D., et al., Occurrence of pregnancy and pregnancy outcomes during isotretinoin therapy. CMAJ, 2016. 188(10): p. 723-730.
15. Azadbakht, M., et al., The Study of Retinoic Acid Effects on Testicular Development of NMRI Mice. Journal of Fasa University of Medical Sciences, 2017. 6(4).
16. Exton, L.S., et al., Compliance with national guidelines on isotretinoin: where are we 2 years since the last audit? Results of the National Isotretinoin Re-Audit 2014. Clin Exp Dermatol, 2017. 42(4): p. 381-389.
17. McDonald, K.A., A.J. Shelley, and A. Alavi, A Systematic Review on Oral Isotretinoin Therapy and Clinically Observable Wound Healing in Acne Patients. J Cutan Med Surg, 2017. 21(4): p. 325-333.
18. Abroms, L., et al., What is the best approach to reducing birth defects associated with isotretinoin? PLoS Med, 2006. 3(11): p. e483.
19. Zomerdijk, I.M., et al., Isotretinoin exposure during pregnancy: a population-based study in The Netherlands. BMJ Open, 2014. 4(11): p. e005602.
20. Amory, J.K., et al., Isotretinoin administration improves sperm production in men with infertility from oligoasthenozoospermia: a pilot study. Andrology, 2017. 5(6): p. 1115-1123.
- Abstract Viewed: 492 times
- PDF Downloaded: 414 times